Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Prostate cancer (PCa) is the most common cancer in men worldwide. Despite better and more intensive treatment options in earlier disease stages, a large subset of patients still progress to metastatic castration-resistant PCa (mCRPC). Recently, poly-(ADP-ribose)-polymerase (PARP)-inhibitors have bee...

Full description

Bibliographic Details
Main Authors: Alexander Giesen, Loïc Baekelandt, Wout Devlies, Gaëtan Devos, Herlinde Dumez, Wouter Everaerts, Frank Claessens, Steven Joniau
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
prostate cancer
HRR genes
synergistic effect (combined treatment)
PARP inhibition (PARPi)
androgen receptor signaling inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1265812/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1265812/full

Similar Items